Showing 5951-5960 of 8181 results for "".
- Study: Azelaic Acid Shows Positive Outcomes in Pregnant Acne Patientshttps://practicaldermatology.com/news/study-azelaic-acid-offers-superior-outcomes-in-pregnant-acne-patients/2483218/New retrospective data on topical therapies for acne vulgaris during pregnancy suggested azelaic acid demonstrated greater efficacy compared to erythromycin or clindamycin. The study, conducted between 2018 and 2022, analyzed
- Bimekizumab Achieves Dual Clearance of Nail and Skin Psoriasishttps://practicaldermatology.com/news/bimekizumab-achieves-dual-clearance-of-nail-and-skin-psoriasis/2483170/In pooled analyses of phase III and IIIb trials, bimekizumab was associated with significantly higher rates of complete clearance of both skin and nail psoriasis compared to adalimumab, ustekinumab, and secukinumab in patients with moderate-to-severe plaque psorias
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://practicaldermatology.com/news/amarte-relaunches-ultra-veil-daily-spf-40/2483087/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release
- Review: Psoriasis May Increase Infection Risk After Hip Arthroplastyhttps://practicaldermatology.com/news/review-psoriasis-may-increase-infection-risk-after-hip-arthroplasty/2483053/Patients with psoriasis undergoing total hip arthroplasty (THA) may face a higher risk of postoperative infection, with evidence regarding total knee arthroplasty (TKA) outcomes remaining inconclusive, according to a new systematic review,
- SSS 2025: Focus on Disruptive Dermatology Innovationshttps://practicaldermatology.com/news/sss-2025-focus-on-disruptive-dermatology-innovations/2482981/The 2025 Science of Skin Summit will debut a new Innovations Forum feature this year dedicated to transformative products and emerging technologies shaping the future of dermatology. Scheduled for Saturday, September 6, 2025,
- Bimekizumab Outperforms IL-17 Inhibitors in Real-World Psoriasis Studyhttps://practicaldermatology.com/news/bimekizumab-shows-edge-over-il-17-inhibitors-in-polish-real-world-psoriasis-study/2482980/Bimekizumab demonstrated a faster and more robust response than secukinumab and ixekizumab in a real-world cohort of Polish patients with moderate-to-severe plaque psoriasis. Researchers conducted a retrospective analysis fro
- DermaRite Recalls Four Skin Care Products Over Burkholderia cepacia Contamination Riskhttps://practicaldermatology.com/news/dermarite-recalls-four-skin-care-products-over-burkholderia-cepacia-contamination-risk/2476092/DermaRite Industries has issued a nationwide recall of four over-the-counter antiseptic and analgesic products after tests detected contamination with Burkholderia cepacia complex (BCC), according to a statement released by
- Switching Biologics for Psoriasis May Improve Outcomes Without Added Risk: Studyhttps://practicaldermatology.com/news/switching-biologics-for-psoriasis-may-improve-outcomes-without-added-risk-study/2476064/Plaque psoriasis patients who are unresponsive to initial biologics may derive benefit from switching to another drug class, according to a new meta-analysis of 24 randomized controlled trials (RCTs). The review looked at da
- Study: Ustekinumab Shows Durability in Real-World Psoriasis Biologic Sequencing Studyhttps://practicaldermatology.com/news/study-ustekinumab-shows-durability-in-real-world-psoriasis-biologic-sequencing-study/2476000/Ustekinumab (Stelara) was associated with the longest treatment duration among biologics used for moderate-to-severe psoriasis, according to results from a recent retrospective real-world analysis. Researchers evaluated health
- FDA Speeds Development of Hair Loss Drug Rezpegaldesleukinhttps://practicaldermatology.com/news/fda-speeds-development-of-nektars-autoimmune-hair-loss-drug/2475953/The FDA has granted Fast Track designation to the investigational biologic rezpegaldesleukin (Nektar Therapeutics) for the treatment of severe-to-very severe alopecia areata (AA) in adults and adolescents aged 12 and older who weigh at least 40 kg.